Stanley G Rockson

List of Publications by Citations

80 papers	3,383 citations	31 h-index	57 g-index
131 ext. papers	4,047 ext. citations	5.5 avg, IF	6.06 L-index

#	Paper	IF	Citations
80	Lymphedema. *American Journal of Medicine*, **2001**, 110, 288-95	2.4	366
79	Estimating the population burden of lymphedema. *Annals of the New York Academy of Sciences*, **2008**, 1131, 147-54	6.5	249
78	Therapeutic lymphangiogenesis with human recombinant VEGF-C. *FASEB Journal*, **2002**, 16, 1985-7	0.9	203
77	New developments in clinical aspects of lymphatic disease. *Journal of Clinical Investigation*, **2014**, 124, 915-21	15.9	191
76	Novel mutations in PIEZO1 cause an autosomal recessive generalized lymphatic dysplasia with non-immune hydrops fetalis. *Nature Communications*, **2015**, 6, 8085	17.4	174
75	Inflammatory manifestations of experimental lymphatic insufficiency. *PLoS Medicine*, **2006**, 3, e254	11.6	163
74	Blockade of transforming growth factor-beta1 accelerates lymphatic regeneration during wound repair. *American Journal of Pathology*, **2010**, 177, 3202-14	5.8	132
73	Th2 differentiation is necessary for soft tissue fibrosis and lymphatic dysfunction resulting from lymphedema. *FASEB Journal*, **2013**, 27, 1114-26	0.9	130
72	Diagnosis and management of lymphatic vascular disease. *Journal of the American College of Cardiology*, **2008**, 52, 799-806	15.1	127
71	Photoangioplasty: An emerging clinical cardiovascular role for photodynamic therapy. *Circulation*, **2000**, 102, 591-6	16.7	105
70	Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. *Journal of the American College of Cardiology*, **2004**, 43, 929-35	15.1	89
69	Precipitating factors in lymphedema: Myths and realities. *Cancer*, **1998**, 83, 2814-2816	6.4	83
68	Leukotriene B antagonism ameliorates experimental lymphedema. *Science Translational Medicine*, **2017**, 9,	17.5	78
67	Lymphedema after Breast Cancer Treatment. *New England Journal of Medicine*, **2018**, 379, 1937-1944	59.2	76
66	Precipitating factors in lymphedema: Myths and realities. *Cancer*, **1998**, 83, 2814-2816	6.4	75
65	Anti-inflammatory pharmacotherapy with ketoprofen ameliorates experimental lymphatic vascular insufficiency in mice. *PLoS ONE*, **2009**, 4, e8380	3.7	70
64	Lymphatic Dysfunction, Leukotrienes, and Lymphedema. *Annual Review of Physiology*, **2018**, 80, 49-70	23.1	61

63	Considerations for Clinicians in the Diagnosis, Prevention, and Treatment of Breast Cancer-Related Lymphedema: Recommendations from a Multidisciplinary Expert ASBrS Panel : Part 1: Definitions, Assessments, Education, and Future Directions. *Annals of Surgical Oncology*, **2017**, 24, 2818-2826	3.1	56
62	The lymphatics and the inflammatory response: lessons learned from human lymphedema. *Lymphatic Research and Biology*, **2013**, 11, 117-20	2.3	54
61	The unique biology of lymphatic edema. *Lymphatic Research and Biology*, **2009**, 7, 97-100	2.3	54
60	Pilot studies demonstrate the potential benefits of antiinflammatory therapy in human lymphedema. *JCI Insight*, **2018**, 3,	9.9	52
59	Cancer-associated secondary lymphoedema. *Nature Reviews Disease Primers*, **2019**, 5, 22	51.1	50
58	Lymphedema prevalence and treatment benefits in cancer: impact of a therapeutic intervention on health outcomes and costs. *PLoS ONE*, **2014**, 9, e114597	3.7	49
57	Current concepts and future directions in the diagnosis and management of lymphatic vascular disease. *Vascular Medicine*, **2010**, 15, 223-31	3.3	46
56	Therapeutic responses to exogenous VEGF-C administration in experimental lymphedema: immunohistochemical and molecular characterization. *Lymphatic Research and Biology*, **2009**, 7, 47-57	2.3	46
55	Considerations for Clinicians in the Diagnosis, Prevention, and Treatment of Breast Cancer-Related Lymphedema, Recommendations from an Expert Panel: Part 2: Preventive and Therapeutic Options. *Annals of Surgical Oncology*, **2017**, 24, 2827-2835	3.1	45
54	The Cutaneous, Net Clinical, and Health Economic Benefits of Advanced Pneumatic Compression Devices in Patients With Lymphedema. *JAMA Dermatology*, **2015**, 151, 1187-93	5.1	39
53	Prospective transcriptomic pathway analysis of human lymphatic vascular insufficiency: identification and validation of a circulating biomarker panel. *PLoS ONE*, **2012**, 7, e52021	3.7	36
52	Aligned nanofibrillar collagen scaffolds - Guiding lymphangiogenesis for treatment of acquired lymphedema. *Biomaterials*, **2016**, 102, 259-267	15.6	35
51	Update on the biology and treatment of lymphedema. *Current Treatment Options in Cardiovascular Medicine*, **2012**, 14, 184-92	2.1	35
50	Causes and consequences of lymphatic disease. *Annals of the New York Academy of Sciences*, **2010**, 1207 Suppl 1, E2-6	6.5	35
49	Addressing the unmet needs in lymphedema risk management. *Lymphatic Research and Biology*, **2006**, 4, 42-6	2.3	25
48	Lymphedema. *Current Treatment Options in Cardiovascular Medicine*, **2006**, 8, 129-36	2.1	24
47	Precipitating factors in lymphedema: myths and realities. *Cancer*, **1998**, 83, 2814-6	6.4	24
46	Myocardial ischemia and infarction due to multiple coronary-cameral fistulae: two case reports and review of the literature. *Catheterization and Cardiovascular Diagnosis*, **1998**, 43, 179-83		22

45	The Lymphatic System in Obesity, Insulin Resistance, and Cardiovascular Diseases. *Frontiers in Physiology*, **2019**, 10, 1402	4.6	20
44	Preclinical models of lymphatic disease: the potential for growth factor and gene therapy. *Annals of the New York Academy of Sciences*, **2002**, 979, 64-75; discussion 76-9	6.5	16
43	Health and economic benefits of advanced pneumatic compression devices in patients with phlebolymphedema. *Journal of Vascular Surgery*, **2019**, 69, 571-580	3.5	14
42	Platelet factor 4 is a biomarker for lymphatic-promoted disorders. *JCI Insight*, **2020**, 5,	9.9	13
41	Pathophysiology of the Lymphatic System in Patients With Heart Failure: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, **2021**, 78, 278-290	15.1	13
40	Reinforcing a continuum of care: in-hospital initiation of long-term secondary prevention following acute coronary syndromes. *Cardiovascular Drugs and Therapy*, **2007**, 21, 375-88	3.9	11
39	Lymphedema. *Current Treatment Options in Cardiovascular Medicine*, **2000**, 2, 237-242	2.1	11
38	Leukotrienes in Tumor-Associated Inflammation. *Frontiers in Pharmacology*, **2020**, 11, 1289	5.6	11
37	Lymphedema After Surgery for Cancer. *Disease Management and Health Outcomes*, **2002**, 10, 345-347		9
36	The lymphatic continuum revisited. *Annals of the New York Academy of Sciences*, **2008**, 1131, ix-x	6.5	8
35	Lymphatic biology and disease: is it being taught? Who is listening?. *Lymphatic Research and Biology*, **2004**, 2, 86-95	2.3	8
34	The lymphatic continuum: the past, present, and exciting future of lymphatic research. *Annals of the New York Academy of Sciences*, **2002**, 979, 1-4; discussion 35-8	6.5	7
33	Advances in Lymphedema. *Circulation Research*, **2021**, 128, 2003-2016	15.7	7
32	Lymphedema after Breast Cancer Treatment. *New England Journal of Medicine*, **2019**, 380, 694	59.2	6
31	Correction of complete thoracic duct obstruction with lymphovenous bypass: A case report. *Microsurgery*, **2019**, 39, 255-258	2.1	5
30	Laboratory models for the investigation of lymphangiomatosis. *Microvascular Research*, **2014**, 96, 64-7	3.7	5
29	Lymphedema therapy in the vascular anomaly patient: therapeutics for the forgotten circulation. *Lymphatic Research and Biology*, **2005**, 3, 253-5	2.3	5
28	Pregnancy Complicated by Gorham-Stout Disease and Refractory Chylothorax. *AJP Reports*, **2016**, 6, e355-e358	1.2	5

27	Benefits of lipid-lowering agents in stroke and coronary heart disease: pharmacoeconomics. *Current Atherosclerosis Reports*, **2000**, 2, 144-50	6	4
26	Decreased lymphatic HIF-2α accentuates lymphatic remodeling in lymphedema. *Journal of Clinical Investigation*, **2020**, 130, 5562-5575	15.9	4
25	The Kinetics of Lymphatic Dysfunction and Leukocyte Expansion in the Draining Lymph Node during LTB Antagonism in a Mouse Model of Lymphedema. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	4
24	Management of lymphatic vascular malformations: A systematic review of the literature. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*, **2021**, 9, 1077-1082	3.2	4
23	Feasibility and Reliability of Rapid Diagnosis of Myocardial Infarction. *American Journal of the Medical Sciences*, **2020**, 359, 73-78	2.2	3
22	Experimental lymphedema: can cellular therapies augment the therapeutic potential for lymphangiogenesis?. *Journal of the American Heart Association*, **2012**, 1, e003400	6	3
21	Lutetium Texaphyrin: A New Therapeutic Tool for Human Atherosclerosis. *Current Treatment Options in Cardiovascular Medicine*, **1999**, 1, 199-202	2.1	3
20	The Lymphatic System **2019**, 45-57		2
19	Appropriate secondary prevention of acute atherothrombotic events and strategies to improve guideline adherence. *Postgraduate Medicine*, **2009**, 121, 25-39	3.7	2
18	Animal models for the mechanistic study of systemic lymphangiomatosis. *Lymphatic Research and Biology*, **2011**, 9, 195-9	2.3	2
17	Research Priorities in Lymphatic Interventions: Recommendations from a Multidisciplinary Research Consensus Panel. *Journal of Vascular and Interventional Radiology*, **2021**, 32, 762.e1-762.e7	2.4	2
16	Exploring disease interrelationships in patients with lymphatic disorders: A single center retrospective experience.. *Clinical and Translational Medicine*, **2022**, 12, e760	5.7	2
15	Literature watch. Hirakawa S, Hong YK, Harvey N, Schacht V, Matsuda K, Libermann T, Detmar M. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol. 2003; 162:575-86. *Lymphatic Research and Biology*, **2004**, 2, 61-4	2.3	1
14	Literature watch. A genetic Xenopus laevis tadpole model to study lymphangiogenesis. *Lymphatic Research and Biology*, **2005**, 3, 263-7	2.3	1
13	Clinical Evaluation of a Novel Wearable Compression Technology in the Treatment of Lymphedema, an Open-Label Controlled Study. *Lymphatic Research and Biology*, **2021**,	2.3	1
12	Hypoxia and Hypoxia-Inducible Factors in Lymphedema.. *Frontiers in Pharmacology*, **2022**, 13, 851057	5.6	1
11	Comorbidity and Lymphatic Disease: The Lymphatic Continuum Re-Examined. *Lymphatic Research and Biology*, **2021**, 19, 17-19	2.3	0
10	General Overview **2018**, 397-401		

9	Medical Treatment Options **2018**, 459-464	
8	Assessing Extracellular Fluid Volume in Breast Cancer Lymphedema. *Lymphatic Research and Biology*, **2013**, 11, 65-65	2.3
7	Literature watch. *Lymphatic Research and Biology*, **2006**, 4, 57-61	2.3
6	Literature watch. Cooke CJ, Nanjee MN, Stepanova IP, Olszewski WL, Miller NE. Variations in lipid and apolipoprotein concentrations in human leg lymph: effects of posture and physical exercise. Atherosclerosis 2004; 173:39-45. *Lymphatic Research and Biology*, **2004**, 2, 147-50	2.3
5	Cardiology Consultation and Management of Perioperative Complications239-247	
4	Lymphatic Development and Implications for Diagnosis and Therapy. *Lymphatic Research and Biology*, **2021**, 19, 31-35	2.3
3	Biomarker Assessment in Lymphedema of the Head and Neck. *Lymphatic Research and Biology*, **2018**, 16, 497-497	2.3
2	New and Emerging Therapies for Lymphedema: Part II **2022**, 209-213	
1	Lymphatic biology and medicine **2022**, 127-137	